Category Archives: Hair Loss Company Stocks

Hair Loss Company Stocks

Hair Loss Companies and their Stock Prices

108 Comments

Hair Loss Company Stock Prices.

I have updated this post several times since first publishing it in 2018 as new companies come and go. Most of the companies in this list make other products in addition to those that just tackle hair loss. I focus on companies that have developed unique reputable products to regrow your hair. Some of these products are currently in clinical trials. Note that several well known companies such as Pelage Pharmaceuticals (US) and OrganTech (Japan) are privately held (so not publicly traded as yet).

  • I do not cover the numerous companies that make products such as: laser hair growth devices; hairpieces; hair systems; shampoos; hair vitamins; and hair loss concealers.
  • I do not cover telehealth companies that specialize in compounding and selling their own hair growth prescription products. You can find a list of some of the largest ones at the top of my post on topical finasteride. I also omit all major generic hair loss drug manufacturers.
  • I do not include companies that make hair transplant related equipment or any other tools (e.g., PRP centrifuges, scalp drug delivery systems, microneedling devices, hair growth measurement and imaging system and so on).
  • I have not covered the numerous companies in South Korea for the time being.

Hair Loss Company Stock Prices

Absci (US): ABSI — This company has been all the rage in 2026. Check out my regularly updated post on Absci and its ABS-201 AI-developed hair loss product that is currently in Phase 1 clinical trials.

Allergan (Ireland): AGN — Working on a number of hair loss products such as Bimatoprost and Setipiprant. Hair loss segment accounts for a small portion of overall sales. Allergan has also invested in several hair loss companies in the recent past.

Coegin Pharma (Ireland): COEGIN — Traded on the Nordic Growth Market for small and medium-sized enterprises. After purchasing Follicum (Sweden) in 2022, this company is developing the latter’s FOL-005 product as a cosmeceutical.

Cosmo Pharmaceuticals (Ireland): COPN — Its Breezula androgen receptor targeting product is causing some excitement and will likely get FDA approval before the end of 2027. The company’s closely related acne fighting topical product Winlevi was released in the US in 2021 and has been a big success.

Eli Lilly (US): LLY — They make Olumiant (baricitinib), an oral JAK inhibitor pill that was approved by the FDA in 2022 to treat adults with severe alopecia areata. More relevant to us androgenetic alopecia (AGA) sufferers, in 2026:

  • In August 2026, Eli Lilly led a group that invested $26 million in US-based Amplifica.
  • In June 2026, Eli Lilly led a group that invested $100 million in US-based Absci (a company I covered above).
  • In February 2026, Eli Lilly purchased 4.9% stake in US-based Veradermics.
  • Eli Lilly was considering investing in the hair and skin regeneration sector of OliX Pharmaceuticals (South Korea). This is after they paid OliX $630m in 2025 for rights to the company’s metabolic-associated steatohepatitis (MASH) drug candidate OLX75016.

Johnson & Johnson (US): JNJ — Although the company makes the original brand name FDA-approved hair loss blockbuster drug Rogaine (Minoxidil), it accounts for a very small portion of overall sales.

Kintor Pharmaceutical (China): KNTPF — Currently in Phase 3 clinical trials, Kintor’s KX-826 product has a high chance of getting approved in China by the end of 2027. It targets the androgen receptor, just like Cosmo’s Breezula, which I discussed earlier.

L’Oreal (France): OR:PA — World renowned cosmetics leader headquartered in France. L’Oreal has been working on 3D printed hair and grey hair reversal treatments for many years. Moreover, in 2026, they made an equity investment in OliX Pharmaceuticals (South Korea) after partnering with them in hair and skin regeneration related research in 2025.

Merck (US): MRK — Although the company makes the original brand name hair loss FDA-approved blockbuster drug Propecia (Finasteride), it accounts for a very small portion of overall sales.

Shiseido (Japan): (SSDOY) — A Japanese cosmetics behemoth that is especially significant in Asia. Basic adenosine based adenovital shampoos and other related hair growth products represent a significant portion of their overall sales. In 2024, Shiseido released its much anticipated DSC cell hair multiplication procedure in Japan.

Veradermics (US): (MANE) — They raised a massive $150 million in financing in 2025 for their extended-release oral minoxidil tablet. Check out my post on Veradermics for the latest updates.

Disclaimer:

I am not a financial advisor or finance professional. As of the time of publishing this post, I do not own shares in any of the above companies.